WO2015061464A3 - Glycoprotéines recombinées et leurs utilisations - Google Patents

Glycoprotéines recombinées et leurs utilisations Download PDF

Info

Publication number
WO2015061464A3
WO2015061464A3 PCT/US2014/061789 US2014061789W WO2015061464A3 WO 2015061464 A3 WO2015061464 A3 WO 2015061464A3 US 2014061789 W US2014061789 W US 2014061789W WO 2015061464 A3 WO2015061464 A3 WO 2015061464A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant
galactosidase
methods
glycoproteins
recombinant glycoproteins
Prior art date
Application number
PCT/US2014/061789
Other languages
English (en)
Other versions
WO2015061464A2 (fr
Inventor
Karen Lee
Christopher HWANG
Christine Demaria
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020167013333A priority Critical patent/KR102298080B1/ko
Priority to MYPI2016700943A priority patent/MY178632A/en
Priority to ES14796346T priority patent/ES2882562T3/es
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Priority to EP14796346.6A priority patent/EP3060660B1/fr
Priority to TN2016000140A priority patent/TN2016000140A1/en
Priority to CN202210146800.9A priority patent/CN114606217A/zh
Priority to JP2016526026A priority patent/JP6837334B2/ja
Priority to DK14796346.6T priority patent/DK3060660T3/da
Priority to CA2927852A priority patent/CA2927852A1/fr
Priority to MX2016005321A priority patent/MX2016005321A/es
Priority to SI201431857T priority patent/SI3060660T1/sl
Priority to PL14796346T priority patent/PL3060660T3/pl
Priority to KR1020217027690A priority patent/KR102479886B1/ko
Priority to RS20210960A priority patent/RS62171B1/sr
Priority to BR112016008086A priority patent/BR112016008086A2/pt
Priority to MYPI2019005029A priority patent/MY197247A/en
Priority to SG11201602932WA priority patent/SG11201602932WA/en
Priority to CN201480070424.3A priority patent/CN105916984A/zh
Priority to MA39053A priority patent/MA39053B2/fr
Priority to UAA201605455A priority patent/UA119857C2/uk
Priority to LTEPPCT/US2014/061789T priority patent/LT3060660T/lt
Priority to AU2014340152A priority patent/AU2014340152A1/en
Priority to EA201690826A priority patent/EA034515B1/ru
Priority to US15/030,555 priority patent/US11208644B2/en
Priority to NZ720384A priority patent/NZ720384A/en
Priority to EP20183936.2A priority patent/EP3778884A1/fr
Publication of WO2015061464A2 publication Critical patent/WO2015061464A2/fr
Publication of WO2015061464A3 publication Critical patent/WO2015061464A3/fr
Priority to DO2016000079A priority patent/DOP2016000079A/es
Priority to PH12016500708A priority patent/PH12016500708A1/en
Priority to IL245255A priority patent/IL245255B/en
Priority to CR20160225A priority patent/CR20160225A/es
Priority to IL272609A priority patent/IL272609B/en
Priority to AU2020294173A priority patent/AU2020294173A1/en
Priority to HRP20211197TT priority patent/HRP20211197T1/hr
Priority to US17/482,193 priority patent/US20220064617A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70592—CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La présente invention concerne des glycoprotéines recombinées (par exemple des protéines de type α-galactosidases A humaines recombinées) présentant un profil de glycosylation modifié (par exemple amélioré), et des compositions pharmaceutiques et des nécessaires comprenant une ou plusieurs de ces protéines. L'invention concerne également des procédés de génération d'une cellule mammifère pouvant être utilisée en vue de l'expression recombinée d'une glycoprotéine (par exemple l'α-galactosidase A humaine recombinée), des procédés de production de glycoprotéines recombinées et des méthodes de traitement impliquant l'administration à un sujet d'au moins une de ces glycoprotéines recombinées (par exemple une protéine de type α-galactosidase A).
PCT/US2014/061789 2013-10-23 2014-10-22 Glycoprotéines recombinées et leurs utilisations WO2015061464A2 (fr)

Priority Applications (34)

Application Number Priority Date Filing Date Title
MA39053A MA39053B2 (fr) 2013-10-23 2014-10-22 Glycoprotéines recombinées et leurs utilisations
ES14796346T ES2882562T3 (es) 2013-10-23 2014-10-22 Glicoproteínas recombinantes y usos de las mismas
CN201480070424.3A CN105916984A (zh) 2013-10-23 2014-10-22 重组糖蛋白及其用途
EP14796346.6A EP3060660B1 (fr) 2013-10-23 2014-10-22 Glycoprotéines recombinées et leurs utilisations
TN2016000140A TN2016000140A1 (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof.
CN202210146800.9A CN114606217A (zh) 2013-10-23 2014-10-22 重组糖蛋白及其用途
JP2016526026A JP6837334B2 (ja) 2013-10-23 2014-10-22 組み換え糖タンパク質及びその使用
DK14796346.6T DK3060660T3 (da) 2013-10-23 2014-10-22 Rekombinante glycoproteiner og anvendelser deraf
CA2927852A CA2927852A1 (fr) 2013-10-23 2014-10-22 Glycoproteines recombinees et leurs utilisations
MX2016005321A MX2016005321A (es) 2013-10-23 2014-10-22 Glicoproteinas recombinantes y sus usos.
SI201431857T SI3060660T1 (sl) 2013-10-23 2014-10-22 Rekombinantni glikoproteini in njihove uporabe
PL14796346T PL3060660T3 (pl) 2013-10-23 2014-10-22 Rekombinowane glikoproteiny i ich zastosowania
MYPI2016700943A MY178632A (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof
RS20210960A RS62171B1 (sr) 2013-10-23 2014-10-22 Rekombinantni glikoproteini i njihova primena
BR112016008086A BR112016008086A2 (pt) 2013-10-23 2014-10-22 Glicoproteínas recombinantes e usos das mesmas
MYPI2019005029A MY197247A (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof
SG11201602932WA SG11201602932WA (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof
KR1020167013333A KR102298080B1 (ko) 2013-10-23 2014-10-22 재조합 당단백질 및 이의 용도
KR1020217027690A KR102479886B1 (ko) 2013-10-23 2014-10-22 재조합 당단백질 및 이의 용도
LTEPPCT/US2014/061789T LT3060660T (lt) 2013-10-23 2014-10-22 Rekombinantiniai glikoproteinai ir jų naudojimas
UAA201605455A UA119857C2 (uk) 2013-10-23 2014-10-22 РЕКОМБІНАНТНИЙ БІЛОК АЛЬФА-ГАЛАКТОЗИДАЗИ-А ЛЮДИНИ (rhAGA)
AU2014340152A AU2014340152A1 (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof
EA201690826A EA034515B1 (ru) 2013-10-23 2014-10-22 Рекомбинантные гликопротеиды и их применения
US15/030,555 US11208644B2 (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof
NZ720384A NZ720384A (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof
EP20183936.2A EP3778884A1 (fr) 2013-10-23 2014-10-22 Glycoprotéines recombinantes et leurs utilisations
DO2016000079A DOP2016000079A (es) 2013-10-23 2016-04-11 Glicoproteinas recombinantes y sus usos
PH12016500708A PH12016500708A1 (en) 2013-10-23 2016-04-15 Recombinant glycoproteins and uses thereof
IL245255A IL245255B (en) 2013-10-23 2016-04-21 Recombinant glycoproteins and their uses
CR20160225A CR20160225A (es) 2013-10-23 2016-05-17 Glicoproteínas recombinantes y sus usos
IL272609A IL272609B (en) 2013-10-23 2020-02-11 Recombinant glycoproteins and their uses
AU2020294173A AU2020294173A1 (en) 2013-10-23 2020-12-21 Recombinant glycoproteins and uses thereof
HRP20211197TT HRP20211197T1 (hr) 2013-10-23 2021-07-26 Rekombinantni glikoproteini i njihova uporaba
US17/482,193 US20220064617A1 (en) 2013-10-23 2021-09-22 Recombinant Glycoproteins and Uses Thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361894879P 2013-10-23 2013-10-23
US61/894,879 2013-10-23
US201361901942P 2013-11-08 2013-11-08
US61/901,942 2013-11-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/030,555 A-371-Of-International US11208644B2 (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof
US17/482,193 Division US20220064617A1 (en) 2013-10-23 2021-09-22 Recombinant Glycoproteins and Uses Thereof

Publications (2)

Publication Number Publication Date
WO2015061464A2 WO2015061464A2 (fr) 2015-04-30
WO2015061464A3 true WO2015061464A3 (fr) 2015-09-03

Family

ID=51871299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/061789 WO2015061464A2 (fr) 2013-10-23 2014-10-22 Glycoprotéines recombinées et leurs utilisations

Country Status (33)

Country Link
US (2) US11208644B2 (fr)
EP (2) EP3060660B1 (fr)
JP (2) JP6837334B2 (fr)
KR (2) KR102479886B1 (fr)
CN (3) CN105916984A (fr)
AU (2) AU2014340152A1 (fr)
BR (1) BR112016008086A2 (fr)
CA (1) CA2927852A1 (fr)
CL (1) CL2016000961A1 (fr)
CR (1) CR20160225A (fr)
DK (1) DK3060660T3 (fr)
DO (1) DOP2016000079A (fr)
EA (1) EA034515B1 (fr)
ES (1) ES2882562T3 (fr)
HR (1) HRP20211197T1 (fr)
HU (1) HUE055236T2 (fr)
IL (2) IL245255B (fr)
LT (1) LT3060660T (fr)
MX (1) MX2016005321A (fr)
MY (2) MY197247A (fr)
NZ (1) NZ720384A (fr)
PE (1) PE20160723A1 (fr)
PH (1) PH12016500708A1 (fr)
PL (1) PL3060660T3 (fr)
PT (1) PT3060660T (fr)
RS (1) RS62171B1 (fr)
SG (2) SG11201602932WA (fr)
SI (1) SI3060660T1 (fr)
TN (1) TN2016000140A1 (fr)
TW (3) TWI793159B (fr)
UA (1) UA119857C2 (fr)
UY (1) UY35794A (fr)
WO (1) WO2015061464A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3458590B9 (fr) * 2016-05-18 2021-08-18 ModernaTX, Inc. Polynucléotides codant pour l' -galactosidase a pour le traitement de la maladie de fabry
BR112019007210A2 (pt) 2016-10-20 2019-08-13 Sangamo Therapeutics Inc métodos e composições para o tratamento da doença de fabry
TW201829770A (zh) * 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
KR20050084473A (ko) 1996-09-13 2005-08-26 트랜스케리오틱 쎄러피스, 인코포레이티드 α-갈락토시다아제 Ａ 결핍을 치료하는 방법
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US20020081654A1 (en) * 2000-04-07 2002-06-27 Sandrin Mauro Sergio Targeting hydrolase enzymes
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7133354B2 (en) 2002-08-26 2006-11-07 Qualcomm Incorporated Synchronization techniques for a wireless system
CA2508925C (fr) * 2002-12-23 2012-08-28 Bristol-Myers Squibb Company Amelioration de la qualite d'un produit dans des procedes de culture de cellules mammiferes en vue de produire des proteines
CN100522988C (zh) * 2003-04-09 2009-08-05 诺和诺德公司 糖peg化方法及由该方法生产的蛋白质/肽
WO2008120107A2 (fr) * 2007-04-03 2008-10-09 Oxyrane (Uk) Limited Glycosylation de molécules
CN101784670A (zh) * 2007-08-31 2010-07-21 弗·哈夫曼-拉罗切有限公司 糖基化谱分析
BRPI1015019A2 (pt) * 2009-04-20 2018-02-14 Pfizer controle de glicosilação de proteína e composições e métodos relacionada a ele.
SI2865751T1 (sl) * 2010-03-02 2017-01-31 Protalix Ltd. Stabilizirana alfa-galaktozidaza in njene uporabe
US20120178105A1 (en) 2011-01-10 2012-07-12 Genzyme Corporation Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich
SI3272861T1 (sl) * 2011-01-20 2020-06-30 Protalix Ltd. Alfa-galaktozidazni sestavki
BR112014008873A2 (pt) * 2011-10-12 2020-09-15 Synageva Biopharma Corp proteína naglu recombinante humana e usos da mesma
EP2620506A1 (fr) 2012-01-25 2013-07-31 Arla Foods Amba Procédé de production de composition contenant des galacto-oligosaccharides
TWI528785B (zh) 2013-02-08 2016-04-01 瑞昱半導體股份有限公司 立體影像的調整裝置及其方法
WO2014137903A2 (fr) 2013-03-08 2014-09-12 Genzyme Corporation Fabrication continue intégrée de substances de médicament de protéine thérapeutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IOANNOU Y A ET AL: "OVEREXPRESSION OF HUMAN ALPHA-GALACTOSIDASE A RESULTS IN ITS INTRACELLULAR AGGREGATION, CRYSTALLIZATION IN LYSOSOMES, AND SELECTIVE SECRETION", THE JOURNAL OF CELL BIOLOGY : JCB, THE ROCKEFELLER UNIVERSITY PRESS, US, vol. 119, no. 5, 1 December 1992 (1992-12-01), pages 1137 - 1150, XP000616658, ISSN: 0021-9525, DOI: 10.1083/JCB.119.5.1137 *
LEE KAREN ET AL: "A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 13, no. 4, 1 April 2003 (2003-04-01), pages 305 - 313, XP002489129, ISSN: 0959-6658, DOI: 10.1093/GLYCOB/CWG034 *
MATSUURA ET AL: "Human alpha-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 8, no. 4, 1 April 1998 (1998-04-01), pages 329 - 339, XP000925912, ISSN: 0959-6658, DOI: 10.1093/GLYCOB/8.4.329 *
YOUNGSOO SOHN ET AL: "Enhanced sialylation and in vivo efficacy of recombinant human [alpha]-galactosidase through in vitro glycosylation", BMB REPORTS, vol. 46, no. 3, 31 March 2013 (2013-03-31), pages 157 - 162, XP055167240, ISSN: 1976-6696, DOI: 10.5483/BMBRep.2013.46.3.192 *

Also Published As

Publication number Publication date
MX2016005321A (es) 2017-01-05
EA201690826A1 (ru) 2016-08-31
RS62171B1 (sr) 2021-08-31
TN2016000140A1 (en) 2017-10-06
PH12016500708A1 (en) 2016-05-30
US11208644B2 (en) 2021-12-28
PT3060660T (pt) 2021-08-06
CN105916984A (zh) 2016-08-31
CL2016000961A1 (es) 2017-02-03
AU2014340152A1 (en) 2016-06-09
US20220064617A1 (en) 2022-03-03
KR20160066550A (ko) 2016-06-10
KR102479886B1 (ko) 2022-12-20
NZ720384A (en) 2022-04-29
JP6837334B2 (ja) 2021-03-03
ES2882562T3 (es) 2021-12-02
UA119857C2 (uk) 2019-08-27
MY178632A (en) 2020-10-19
TW201610163A (zh) 2016-03-16
CA2927852A1 (fr) 2015-04-30
PE20160723A1 (es) 2016-08-01
PL3060660T3 (pl) 2021-12-06
IL272609A (en) 2020-03-31
DK3060660T3 (da) 2021-09-13
EP3060660A2 (fr) 2016-08-31
TW201900873A (zh) 2019-01-01
CN112852784A (zh) 2021-05-28
JP2016538840A (ja) 2016-12-15
JP2020089379A (ja) 2020-06-11
MY197247A (en) 2023-06-08
UY35794A (es) 2015-05-29
HUE055236T2 (hu) 2021-11-29
TWI793159B (zh) 2023-02-21
KR20210111880A (ko) 2021-09-13
US20160264953A1 (en) 2016-09-15
EP3060660B1 (fr) 2021-06-23
KR102298080B1 (ko) 2021-09-06
IL245255B (en) 2020-02-27
SG10201803366PA (en) 2018-05-30
WO2015061464A2 (fr) 2015-04-30
DOP2016000079A (es) 2016-05-30
SG11201602932WA (en) 2016-05-30
BR112016008086A2 (pt) 2017-10-03
CR20160225A (es) 2016-06-24
JP7296327B2 (ja) 2023-06-22
SI3060660T1 (sl) 2021-09-30
IL245255A0 (en) 2016-06-30
AU2020294173A1 (en) 2021-02-11
IL272609B (en) 2022-03-01
LT3060660T (lt) 2021-07-26
EA034515B1 (ru) 2020-02-14
TWI642782B (zh) 2018-12-01
EP3778884A1 (fr) 2021-02-17
CN114606217A (zh) 2022-06-10
HRP20211197T1 (hr) 2021-11-12
TW202332774A (zh) 2023-08-16

Similar Documents

Publication Publication Date Title
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
WO2016070166A3 (fr) Molécules d'una messager et leurs utilisations
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
WO2014052360A3 (fr) Préparations de glycoprotéines
WO2016037154A8 (fr) Protéines de l'enveloppe du vih-1 recombinantes et leur utilisation
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
MX355469B (es) Complejos de proteinas de citomegalovirus.
WO2019002512A3 (fr) Glycoprotéines sur mesure issues de l'ingenierie et entièrement fonctionnelles
MX2018011162A (es) Metodos de purificacion de colageno 7.
PH12016500708A1 (en) Recombinant glycoproteins and uses thereof
TW201613964A (en) Improved A[beta] protofibril binding antibodies
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
WO2013109190A3 (fr) Expression de protéine recombinante cho-gmt
BR112019000837A2 (pt) células miméticas de célula b
MX2018016417A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas.
SG10201803999UA (en) Recombinant factor viii formulations
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
PH12015502037A1 (en) Activating adiponectin by casein hydrolysate
WO2015120527A3 (fr) Amélioration de l'expression de protéines recombinées au moyen d'un système de rétention de cellules basé sur une membrane
PH12017501979A1 (en) Pharmaceutical compound
WO2015003811A8 (fr) Procédés d'obtention de protéines thérapeutiques sialylées
CA2898614C (fr) Ciblage de proteines gli a l'aide de petites molecules dans un cancer humain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14796346

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2927852

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12016500708

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 15030555

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 245255

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2016526026

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 000543-2016

Country of ref document: PE

Ref document number: MX/A/2016/005321

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016008086

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 16120696

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: CR2016-000225

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 20167013333

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201690826

Country of ref document: EA

Ref document number: A201605455

Country of ref document: UA

Ref document number: IDP00201603378

Country of ref document: ID

Ref document number: 39053

Country of ref document: MA

REEP Request for entry into the european phase

Ref document number: 2014796346

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014796346

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014340152

Country of ref document: AU

Date of ref document: 20141022

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016008086

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160412